China Biologic Products will pay $28.5 million to gain control of one of its competitors in the business of plasma-based pharmaceuticals. China Biologic will buy a 90% stake in Chongqing Dalin Biologic Technologies Co., Ltd. Dalin, in turn, owns a 54% equity interest in Qianfeng Biological Products Co., Ltd., which makes plasma-based products. Qianfeng is a bigger business that China Biologic. It has a 9.5% market share of China’s plasma-based biopharma business, while China Biologic can claim only 6.1%. More details...

Stock Symbol: (OTCBB: CBPO)